You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Applicability of BARD score to Japanese patients with NAFLD
  1. H Fujii1,
  2. M Enomoto1,
  3. W Fukushima2,
  4. A Tamori1,
  5. H Sakaguchi1,
  6. N Kawada1
  1. 1
    Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, Japan
  2. 2
    Department of Public Health, Graduate School of Medicine, Osaka City University, Osaka, Japan
  1. Correspondence to Dr N Kawada, Department of Hepatology, Graduate School of Medicine, Osaka City University, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan; kawadanori{at}med.osaka-cu.ac.jp

https://doi.org/10.1136/gut.2009.182758

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read the article by Harrison et al1 with great interest. The authors proposed an easily calculated composite score for predicting the risk of advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD), called the BARD score: the weighted sum of the three variables (body mass index (BMI) ⩾28 = 1 point, aspartate aminotransferase/alanine aminotransferase ratio (AAR) ⩾0.8 = 2 points, diabetes = 1 point). When a BARD score of 2–4 was used, the area under the receiver operating characteristic curve (AUROC) was found to be 0.81 with an odds ratio (OR) of 17 (95% CI 9.2 to 31.9) for detecting advanced fibrosis. The positive predictive value (PPV) and negative predictive value (NPV) were 43% and 96%, respectively. We studied the reliability of the BARD score for identifying …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and Peer review Not commissioned; not externally peer reviewed.